ArticleMedicina oral, patologia oral y cirugia bucal2025
Histological and morphometrical evaluation of non-critical bone defects after treatment with biomaterial and bisphosphonates.
Article in Medicina oral, patologia oral y cirugia bucal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biofunctional response of a synthetic ceramic of 99.9% tricalcium phosphate associated with a heterologous fibrin biopolymer and infrared photobiomodulation.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary goal of this in vivo study was to ascertain if systemic bisphosphonates (BPs) positively affect bone repair in non-critical defects when assisted with a carbonated hydroxyapatite graft biomaterial (Biomat). MATERIAL AND
methodsThirty-six female rats were allocated into two control groups (blood clot [BC] and alloplastic biomaterial); two groups with zoledronate (third-generation BPs): Zol.BP and Zol.BP+Biomat; and two groups with clodronate (first-generation BPs): Clod.BP and the Clod.BP+Biomat. The experimental groups started the application of BP 60 days before surgery. Then, a 2 mm non-critical defect was performed in the rats' femur and filled according to the group. All animals were euthanized 30 days after surgery, and the samples were collected for histological and histomorphometry analysis, respectively, for descriptive and quantitative analyses.
resultsZol.BP+Biomat had greater new bone formation, whereas clodronate presented high osteogenic potential, significantly increasing the observed levels of newly formed bone even in the absence of the biomaterial. Histomorphometrically, BC had 2% bone formation compared to the biomaterial group (5%). Zol.BP and Col.BP achieved bone formation of 6-fold (12%, p>0.05) and 9.5-fold (19%, p<0.05), respectively, when compared with BC. Zol.BP+Biomat group presented the highest value found for newly formed bone (24%), 12-fold more than BC (p<0.001) and 4.8-fold more than the biomaterial group (p<0.01).
conclusionsIt is possible to conclude that the systemic use of BP positively affected non-critical bone defects when associated with biomaterials, mainly when the third generation of BPs was used in this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.